Navigation Links
Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Date:1/14/2009

rt an optimal therapeutic dose level of 50 kBq/kg as selected for use in the global phase III ALSYMPCA trial (see below for further details).

Furthermore, the successful completion of the phase II program also supports Algeta's strategy for targeting Alpharadin at patients with metastatic HRPC who are unsuitable or who have failed docetaxel chemotherapy and for first-line use in combination with docetaxel. A combination study is in preparation, which if successful will enable Algeta to market Alpharadin, either alone or in combination with docetaxel, to approximately 85% of the global HRPC market.

Algeta's President and CEO, Dr. Thomas Ramdahl, said: "The completion of the phase II program is an important milestone for Algeta that gives us great confidence in the potential of Alpharadin as a new, safe and effective treatment for metastatic prostate cancer. The program has demonstrated not only that Alpharadin can improve patient quality of life by successfully treating the painful and debilitating bone metastases arising from the primary cancer, but also that it has a proven survival benefit for patients. We believe there is not a single cancer therapeutic available today offering these patients such clinical benefits, let alone one which is so readily tolerated. We remain confident that the phase III clinical program will confirm these impressive results and support a strong case for regulatory approval in due course."

Dr Chris Parker, a prostate cancer specialist based at the Institute of Cancer Research and the Royal Marsden Hospital in Sutton, UK, and the study's principal investigator, said: "The clinical results generated so far for Alpharadin in treating metastatic prostate cancer are highly encouraging and offer patients the possibility of an effective treatment that both prolongs life while also maintaining quality of life. In addition, the results announced today further emphasize the remark
'/>"/>

SOURCE Algeta
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
2. MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
5. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
7. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
8. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
9. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
10. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will ... the Australian and New Zealand Forensic Science Society,s ... Sciences in Adelaide, Australia . ... concerning the advancements that hyperspectral imaging can bring ... Jeffrey Beckstead , Director of Product Development at ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com announces that ... its catalogue: North America Aesthetic Lasers ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North ... to 2020 Summary GlobalData,s new report, ... Outlook to 2020", provides key market data on ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a ... Phase 3 study required for New Drug Application (NDA) ... 140 patients has greater than 90% power to detect ... to enrol additional patients. QRxPharma anticipates completing analysis of ...
... or "Company") (Nasdaq: UNIS, ASX: UNS), today announced that ... clearance from the U.S. Food and Drug Administration (FDA). ... variant of the Unitract™ 1mL Insulin Syringe for which ... syringes which are primarily used by people with diabetes, ...
Cached Medicine Technology:QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 2QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 3Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 2Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 3
(Date:8/30/2014)... (PRWEB) August 30, 2014 Daily Gossip reveals ... the Make Him Desire You program, who shows a unique ... The author of this method says that the program goes ... The Make Him Desire You review indicates that the program ... insider advice and his great techniques to make a man ...
(Date:8/30/2014)... Albany, New York (PRWEB) August 30, 2014 ... a combination of Nutrition and Pharameuticals. Nutraceuticals is ... by extracting healthy ingredients from natural food sources. ... specific health benefits to the human body. Nutraceutical ... multivitamins, diet supplements, fortified foods and more. Although ...
(Date:8/30/2014)... Tenn. (PRWEB) August 30, 2014 ... around the country for the past several years, ... Tennessee Hyperbaric Center have announced a scholarship program ... This announcement follows a meeting held this summer ... In recent years, reporters have shed light on ...
(Date:8/30/2014)... York, New York (PRWEB) August 30, 2014 ... other incretin mimetic claims continue to move forward in ... statement issued by AstraZeneca PLC on July 31, 2014, ... been named in 409 product liability claims that allege ... Court documents indicate that many of these claims are ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... say , , MONDAY, Dec. 1 (HealthDay News) -- ... non-invasive treatment for the painful foot condition known ... "dry-needling" and steroid injections guided by ultrasound, the ... success rate in tackling a condition that afflicts ...
... NASHVILLE, Tenn., Dec. 1 Medication therapy management,(MTM) provider ... , New members ... Burcham; and Kevin Hutchinson. The three join an ... hone its MTM services, which work,to guard against medication ...
... Dec. 1 Seniors who take a close look ... plans may still realize,savings next year. Medicare HMO ... $0 monthly premiums and $0 deductibles with partial coverage,throughout ... of their,drug bills until reaching $4,350 in out-of-pocket costs). ...
... Dec. 1 The next time you visit a dentist,in ... blood pressure,in addition to your brushing habits. , ... Medical Center/McLaren Health,Care and the Michigan Primary Care Association are ... together more closely on,detecting high blood pressure in patients. , ...
... stenosis, according to a large study performed at Leiden ... The study consisted of 1,331 patients who had suspected ... coronary artery segments were analyzed during the study. "We ... artery stenosis in our patients; specificity was 91%," said ...
... UCLA study shows for the first time how microscopic crystals ... at the ends of cilia tiny cellular hairs in ... play an important role in detecting sound, maintaining balance and ... to blame for the most common form of vertigo. Known ...
Cached Medicine News:Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3Health News:PharmMD Expands Advisory Board 2Health News:HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2009 Out-of-Pocket Drug Costs 2Health News:Dental and Medical Communities Piloting Partnership in Mid-Michigan To Detect and Defeat Disease 2Health News:Dental and Medical Communities Piloting Partnership in Mid-Michigan To Detect and Defeat Disease 3Health News:Can you hear me now? How the inner ear's sensors are made 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: